|
Encouraging Results from Flurizan Clinical Trial
Dr. Robert C. Green. |
Results from the Flurizan
Study were recently
presented at the national
Society for Neuroscience
meeting. The Phase 2 trial
of Flurizan monitored patients
at which time the group of
mild patients taking Flurizan
showed less decline in
cognition (as measured by
the ADAS-cog scale) than
did the placebo group.
Patients with mild AD on
Flurizan were then followed for 3 additional months
score; by 18 months their mean score was further
elevated, for a total average improvement of 33%.
A Phase 3 trial is now underway at 100 sites nationwide.
Dr. Robert C. Green of the BU ADC is one of
two lead investigators on the national study, as well
as its site director at BU. He commented, “We are
excited to be providing this compound to Boston
area patients with mild AD. The Phase 2 results are
encouraging, and the Phase 3 trial will answer the
question of whether this compound is effective or
not. If it is, we will have an entirely new and exciting
approach to treating AD.”
For more study information,
contact Mayuri Thakuria at 617-638-5619.
Alzheimer's Disease Neuroimaging Initiative
Recruitment is now underway at the BU site of the
nationalAlzheimer’s Disease Neuroimaging Initiative
(ADNI). ADNI is a $60 million, 5 year public-private
partnership, sponsored by the NIH, to determine
whether brain imaging can help predict onset
and monitor progression of AD. The study is taking
place at approximately 50 sites across the U.S. and
Canada. The noted poet and author Maya Angelou
has recently been named a national spokesperson for
the project.
For more information, contact Patrick
Compton at 617-414-1196..
Risk Evaluation & Education for Alzheimer's Disease
(REVEAL)
The REVEAL Study (Robert C. Green, Principal Investigator)
is the fi rst study to examine the impact
of providing genetic susceptibility testing to adult
children of people with AD. A totaFebruary 26, 2006te clinical
trial, including 86 individuals here at BU. The study
is now closed to new enrollment, and we are more
than halfway through data collection. An application
for renewed funding for the study has been
submitted to the National Institutes of Health. An overview of results from the first REVEAL clinical
trial was published in the December 2005 Journal
of Geriatric Psychiatry & Neurology (Scott Roberts,
lead author).
|
